Skip to main content
Log in

Influence des polymorphismes génétiques sur la variabilité de la réponse aux opioïdes

Influence of genetic polymorphisms on the response variability to opioids

  • Article de Synthèse / Review Article
  • Published:
Douleur et Analgésie

Résumé

Malgré des progrès considérables dans la gestion de la douleur et dans la compréhension de ses mécanismes neurobiologiques, le choix du médicament et de la posologie d’antalgique associé à un rapport bénéfice/risque optimal reste un défi en raison de variabilités interindividuelles aux analgésiques liées à des facteurs génétiques et environnementaux. Le but de cette revue est de présenter brièvement les données disponibles les plus pertinentes sur la variabilité interindividuelle pharmacocinétique (PK) et pharmacodynamique (PD) causée par des polymorphismes nucléotidiques SNPs (Single-Nucleotide Polymorphisms) et leur conséquence clinique sur l’efficacité analgésique des opioïdes.

Abstract

Despite the remarkable progress in pain management and the understanding of its neurobiological mechanisms, the choice of appropriate analgesic drug and the dose associated to an optimal benefit/risk remains a challenge because of the variability due to genetic and environmental factors. The aim of this review is to present a summary of most relevant available data on pharmacokinetic (PK) and pharmacodynamic (PD) inter-individual variability caused by SNPs (Single-Nucleotide Polymorphisms) and their clinical consequences on the analgesic efficacy of opioids.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Références

  1. Campa D, Gioia A, Tomei A, et al (2008) Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 83:559–566

    Article  CAS  PubMed  Google Scholar 

  2. Chou WY, Wang CH, Liu PH, et al (2006) Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 105:334–337

    Article  CAS  PubMed  Google Scholar 

  3. Chou WY, Yang LC, Lu HF, et al (2006) Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 50:787–792

    Article  CAS  PubMed  Google Scholar 

  4. Coller JK, Barratt DT, Dahlen K, et al (2006) ABCB1 genetic variability and methadone dosage requirements in opioiddependent individuals. Clin Pharmacol Ther 80:682–690

    Article  CAS  PubMed  Google Scholar 

  5. Coulbault L, Beaussier M, Verstuyft C, et al (2006) Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther 79:316–324

    Article  CAS  PubMed  Google Scholar 

  6. Crettol S, Deglon JJ, Besson J, et al (2005) Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78:593–604

    Article  CAS  PubMed  Google Scholar 

  7. Crews KR, Gaedigk A, Dunnenberger HM, et al (2012) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 91:321–326

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Darbari DS, van Schaik RH, Capparelli EV, et al (2008) UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol 83:200–202

    Article  CAS  PubMed  Google Scholar 

  9. Dayer P, Desmeules J, Leemann T, et al (1988) Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun 152:411–416

    Article  CAS  PubMed  Google Scholar 

  10. de Leon J, Armstrong SC, Cozza KL (2006) Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 47:75–85

    Article  PubMed  Google Scholar 

  11. Desmeules J, Gascon MP, Dayer P, et al (1991) Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 41:23–26

    Article  CAS  PubMed  Google Scholar 

  12. Drewe J, Ball HA, Beglinger C, et al (2000) Effect of Pglycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Br J Clin Pharmacol 50:237–246

    Article  CAS  PubMed  Google Scholar 

  13. Eichelbaum M, Evert B (1996) Influence of pharmacogenetics on drug disposition and response. Clin Exp Pharmacol Physiol 23:983–985

    Article  CAS  PubMed  Google Scholar 

  14. Fernandez Robles CR, Degnan M, Candiotti KA (2012) Pain and genetics. Curr Opin Anaesthesiol 25:444–449

    Article  CAS  PubMed  Google Scholar 

  15. Finco G, Pintor M, Sanna D, et al (2012) Is target opioid therapy within sight? Minerva Anestesiol 78:462–72

    CAS  PubMed  Google Scholar 

  16. Fujita K, Ando Y, Yamamoto W, et al (2010) Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother Pharmacol 65:251–258

    Article  CAS  PubMed  Google Scholar 

  17. Gasche Y, Daali Y, Fathi M, et al (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351:2827–2831

    Article  CAS  PubMed  Google Scholar 

  18. Kadiev E, Patel V, Rad P, et al (2008) Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin Drug Metab Toxicol 4:77–91

    Article  CAS  PubMed  Google Scholar 

  19. Kelly LE, Madadi P (2012) Is there a role for therapeutic drug monitoring with codeine? Ther Drug Monit 34:249–256

    Article  CAS  PubMed  Google Scholar 

  20. Kharasch ED, Hoffer C, Altuntas TG, et al (2004) Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. J Clin Pharmacol 44:224–233

    Article  CAS  PubMed  Google Scholar 

  21. Kharasch ED, Hoffer C, Whittington D (2004) The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br J Clin Pharmacol 57:600–610

    Article  CAS  PubMed  Google Scholar 

  22. Levran O, O’Hara K, Peles E, et al (2008) ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 17:2219–2227

    Article  CAS  PubMed  Google Scholar 

  23. Lewis AJ, Kelly MM, Walle UK, et al (1996) Improved bacterial expression of the human P form phenolsulfotransferase. Applications to drug metabolism. Drug Metab Dispos 24:1180–1185

    CAS  Google Scholar 

  24. Lotsch J, Geisslinger G (2006) Current evidence for a genetic modulation of the response to analgesics. Pain 121:1–5

    Article  PubMed  Google Scholar 

  25. Lotsch J, Geisslinger G, Tegeder I (2009) Genetic modulation of the pharmacological treatment of pain. Pharmacol Ther 124: 168–184

    Article  PubMed  Google Scholar 

  26. Lotsch J, Skarke C, Wieting J, et al (2006) Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther 79:72–89

    Article  PubMed  Google Scholar 

  27. Lotsch J, von Hentig N, Freynhagen R, et al (2009) Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics 19:429–436

    Article  PubMed  Google Scholar 

  28. Madadi P, Koren G, Cairns J, et al (2007) Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 53:33–35

    PubMed  PubMed Central  Google Scholar 

  29. Muralidharan A, Smith MT (2011) Pain, analgesia and genetics. J Pharm Pharmacol 63:1387–1400

    Article  CAS  PubMed  Google Scholar 

  30. Norbury TA, MacGregor AJ, Urwin J, et al (2007) Heritability of responses to painful stimuli in women: a classical twin study. Brain 130:3041–3049

    Article  PubMed  Google Scholar 

  31. Overholser BR, Foster DR (2011) Opioid pharmacokinetic drugdrug interactions. Am J Manag Care 17 Suppl 11:S276–S287

    PubMed  Google Scholar 

  32. Park HJ, Shinn HK, Ryu SH, et al (2007) Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther 81:539–546

    Article  CAS  PubMed  Google Scholar 

  33. Rakvag TT, Klepstad P, Baar C, et al (2005) The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116:73–78

    Article  CAS  PubMed  Google Scholar 

  34. Reyes-Gibby CC, Shete S, Rakvag T, et al (2007) Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 130:25–30

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Sakurai A, Tamura A, Onishi Y, et al (2005) Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications. Expert Opin Pharmacother 6:2455–2473

    Article  CAS  PubMed  Google Scholar 

  36. Samer CF, Daali Y, Wagner M, et al (2010) Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol 160:919–930

    Article  CAS  PubMed  Google Scholar 

  37. Sawyer MB, Innocenti F, Das S, et al (2003) A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 73:566–574

    Article  CAS  PubMed  Google Scholar 

  38. Somogyi AA, Barratt DT, Coller JK (2007) Pharmacogenetics of opioids. Clin Pharmacol Ther 81:429–444

    Article  CAS  PubMed  Google Scholar 

  39. Stamer UM, Lehnen K, Hothker F, et al (2003) Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 105:231–238

    Article  CAS  PubMed  Google Scholar 

  40. Stamer UM, Stuber F (2007) Codeine and tramadol analgesic efficacy and respiratory effects are influenced by CYP2D6 genotype. Anaesthesia 62:1294–1295; author reply 1295–6

    Article  CAS  PubMed  Google Scholar 

  41. Stamer UM, Zhang L, Book M, et al (2013) CYP2D6 genotype dependent oxycodone metabolism in postoperative patients. PLoS One 8:e60239

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Turabi A, Plunkett AR (2012) The application of genomic and molecular data in the treatment of chronic cancer pain. J Surg Oncol 105:494–501

    Article  CAS  PubMed  Google Scholar 

  43. Walter C, Lotsch J (2009) Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 146: 270–275

    Article  CAS  PubMed  Google Scholar 

  44. Zubieta JK, Heitzeg MM, Smith YR, et al (2003) COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299:1240–1243

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to N. Marsousi.

About this article

Cite this article

Marsousi, N., Ancrenaz, V., Daali, Y. et al. Influence des polymorphismes génétiques sur la variabilité de la réponse aux opioïdes. Douleur analg 26, 203–208 (2013). https://doi.org/10.1007/s11724-013-0358-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11724-013-0358-4

Mots clés

Keywords

Navigation